The company will look for treatments for tricky ailments, such as drug-resistant tuberculosis, Zika, hepatitis B and HIV.
A revolutionary treatment for cancer hits the U.S. market this year, but it can't be stockpiled.
A handful of very wealthy patrons are using unconventional tactics to get game-changing drugs to market faster.